Compare iShares MSCI Singapore ETF (EWS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Summit Therapeutics Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.6 (market cap $1.49B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 9.2× iShares MSCI Singapore ETF's market cap, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and Summit Therapeutics Inc for 16 Days on average.
| EWS | SMMT | |
|---|---|---|
Market Cap | $1.49B | $13.71B |
Volume | 2,142,305 | 6,173,057 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $26.38 |
52-Week Low | $26.71 | $12.43 |
Typical Hold Time | 45 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS (iShares MSCI Singapore ETF) trades at $31.60, down 2.71% with bearish technical signals from moving averages and oscillators. The ETF recently hit 52-week highs amid Singapore's strong economic growth and AI momentum, attracting institutional interest including Amundi's 4.8% position increase. Key support sits at $31 with resistance at $32.
Outlook remains mixed with technical weakness offset by positive fundamental drivers. Investment opportunity lies in Singapore's economic resilience and AI-driven growth, though stretched valuations and bearish momentum present near-term risks. The ETF offers exposure to Asia's outperformance versus S&P 500 but faces volatility from regional economic sensitivity.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
